1,369 reports of this reaction
1.8% of all OLMESARTAN MEDOXOMIL reports
#11 most reported adverse reaction
HAEMORRHOIDS is the #11 most commonly reported adverse reaction for OLMESARTAN MEDOXOMIL, manufactured by Cosette Pharmaceuticals, Inc.. There are 1,369 FDA adverse event reports linking OLMESARTAN MEDOXOMIL to HAEMORRHOIDS. This represents approximately 1.8% of all 74,967 adverse event reports for this drug.
OLMESARTAN MEDOXOMIL has an overall safety score of 85 out of 100. Patients taking OLMESARTAN MEDOXOMIL who experience haemorrhoids should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HAEMORRHOIDS is a less commonly reported adverse event for OLMESARTAN MEDOXOMIL, but still significant enough to appear in the safety profile.
In addition to haemorrhoids, the following adverse reactions have been reported for OLMESARTAN MEDOXOMIL:
The following drugs have also been linked to haemorrhoids in FDA adverse event reports:
HAEMORRHOIDS has been reported as an adverse event in 1,369 FDA reports for OLMESARTAN MEDOXOMIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HAEMORRHOIDS accounts for approximately 1.8% of all adverse event reports for OLMESARTAN MEDOXOMIL, making it a notable side effect.
If you experience haemorrhoids while taking OLMESARTAN MEDOXOMIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.